An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

[1]  W. Grant.  Racial disparities for uterine corpus tumors , 2009, Cancer.

[2]  L. Havrilesky,et al.  Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma , 2009, Cancer.

[3]  P. Schiff,et al.  Racial disparities for uterine corpus tumors , 2009, Cancer.

[4]  A. Secord,et al.  Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. , 2009, Gynecologic oncology.

[5]  L. Havrilesky,et al.  Chemotherapy With or Without Radiation Therapy Favorably Impacts Survival Outcomes in Stage I Uterine Papillary Serous Carcinoma , 2009 .

[6]  M. Einstein,et al.  Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). , 2008, Gynecologic oncology.

[7]  A. Mariani,et al.  Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. , 2007, Gynecologic oncology.

[8]  Tina A. Ayeni,et al.  Outcomes in surgical stage I uterine papillary serous carcinoma. , 2007, Gynecologic oncology.

[9]  G. Gitsch,et al.  Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma. , 2007, Anticancer research.

[10]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[11]  R. Kryscio,et al.  The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). , 2005, Gynecologic oncology.

[12]  J. McAlpine,et al.  Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. , 2005, Gynecologic oncology.

[13]  E. Siegel,et al.  Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. , 2005, American journal of obstetrics and gynecology.

[14]  N. Sneige,et al.  Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Wiegel,et al.  Induction of multidrug resistance on mRNA and on protein level by fractionated irradiation , 2004 .

[16]  P. Maisonneuve,et al.  Carcinoma of the corpus uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[17]  M. Sherman,et al.  Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus , 2003, Cancer.

[18]  P. Maisonneuve,et al.  Carcinoma of the Corpus Uteri , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  R. Scully,et al.  Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. , 1995, Gynecologic oncology.

[20]  J. Cain,et al.  Uterine papillary serous carcinoma: patterns of metastatic spread. , 1994, Gynecologic oncology.

[21]  M. Sherman,et al.  Uterine Serous Carcinoma A Morphologically Diverse Neoplasm With Unifying Clinicopathologic Features , 1992, The American journal of surgical pathology.

[22]  R. Kempson,et al.  Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.